Influence of 5-HT(1A) receptor antagonism on plus-maze behaviour in mice. II. WAY 100635, SDZ 216-525 and NAN-190

Pharmacology Biochemistry and Behavior

Volumn 58, Issue 2, 1997, Pages 593-603

  Cao, B J ^a   Rodgers, R J ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

1 Adrenoceptors; 5 HT(1A) receptors; Anxiety; Elevated plus maze; Mice; NAN 190; Prazosin; SDZ 216 525; WAY 100635

Indexed keywords

1 (2 METHOXYPHENYL) 4 (4 PHTHALIMIDOBUTYL)PIPERAZINE; 4 [4 [4 (1,1,3 TRIOXO 2H 1,2 BENZISOTHIAZOL 2 YL)BUTYL] 1 PIPERAZINYL] 1H INDOLE 2 CARBOXYLIC ACID METHYL ESTER; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; PRAZOSIN; RECEPTOR SUBTYPE; SEROTONIN 1A ANTAGONIST; SEROTONIN 1A RECEPTOR; 1 (2 METHOXYPHENYL) 4 (4 (2 PHTHALIMIDO)BUTYL)PIPERAZINE; 1-(2-METHOXYPHENYL)-4-(4-(2-PHTHALIMIDO)BUTYL)PIPERAZINE; INDOLE DERIVATIVE; PIPERAZINE DERIVATIVE; PYRIDINE DERIVATIVE; SDZ 216-525; SEROTONIN 1 RECEPTOR; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR; THIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANXIETY; ARTICLE; BEHAVIOR; CONTROLLED STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; MAZE TEST; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; ANIMAL; ANIMAL BEHAVIOR; DOSE RESPONSE; DRUG EFFECT;

ANIMALS; BEHAVIOR, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; INDOLES; MALE; MAZE LEARNING; MICE; PIPERAZINES; PYRIDINES; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; SEROTONIN ANTAGONISTS; THIAZOLES;

EID: 0030609834     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(97)00279-7     Document Type: Article

References (66)

1. Ahlers S. T., Weissman B. A., Barrett J. E. Antagonism studies with BMY-7378 and NAN-190. effects on 8-hydroxy-2-(di-n-propylamino)tetralin-induced increases in punished responding of pigeons J. Pharmacol. Exp. Ther. 260:1992;474-481.
2. Al-Maiki S. J., Al-Hamood M. H. Effects of alpha and beta adrenergic antagonists on aggressive behavior in male mice. Aggr. Behav. 19:1993;361-367.
3. 1A receptors in the median raphe nucleus and dorsal hippocampus may mediate anxiolytic and anxiogenic behaviours respectively. Eur. J. Pharmacol. 264:1994;259-264.
4. 1A receptor antagonists on hippocampal 5-hydroxytryptamine levels. (S)-WAY100135, but not WAY 100635, has partial agonist properties Eur. J. Pharmacol. 304:1996;15-21.
5. Bell R., Hobson H. Effects of (-)-pindolol and SDZ 216-525 on social and agonistic behavior in mice. Pharmacol. Biochem. Behav. 46:1993;873-880.
6. 1A receptor antagonists (+) WAY 100135 and WAY 100635. Neuropharmacology. 34:1995;805-811.
7. 1A receptor ligands in the mouse. Br. J. Pharmacol. 111:1994;151P.
8. Bill D. J., Knight M, Forster E. A., Fletcher A. Direct evidence for an important species difference in the mechanism of 8-OH-DPAT-induced hypothermia. Br. J. Pharmacol. 103:1991;1857-1864.
9. 1A receptor antagonist (S)-fluoro-8-hydroxy-2-(dipropylamino)tetralin. inhibition of (R)-8-hydroxy-2-(dipropylamino) tetralin-induced effects J. Pharmacol. Exp. Ther. 258:1991;58-65.
10. Cadogan A. K., Kendall D. A., Fink H., Marsden C. A. Social interaction increases 5-HT release and cAMP efflux in the rat ventral hippocampus in vivo. Behav. Pharmacol. 5:1994;299-305.
11. Cao B.-J., Rodgers R. J. Different behavioural profiles of R(+)- and S(-)-enantiomers of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) in the murine elevated plus-maze. Behav. Pharmacol.; 7:1996;810-819.
12. 1A receptor antagonist, has anxiolytic-like profile in the murine elevated plus-maze. Psychopharmacology; 129:1997;365-371.
13. 1A. Pharmacol. Biochem. Behav. 58:1997;583-591.
14. 3) receptor antagonists increase rates of punished responding in rats. Pharmacol. Biochem. Behav. 52:1995;671-676.
15. 1A receptor ligands on a safety signal withdrawal procedure of conflict in the rat. Pharmacol. Biochem. Behav. 48:1994;281-289.
16. 1A receptor antagonist NAN-190 on rat brain serotonergic transmission. Eur. J. Pharmacol. 204:1991;71-77.
17. 1A receptor antagonists. Curr. Drugs Serotonin. 1:1993;99-124.
18. 1A antagonist, WAY 100635. J. Psychopharmacol. 10:1996;A46.
19. 1A receptor agonists recent developments and controversial issues. Psychopharmacolog. y(121):1995;1-26.
20. 1A-receptor ligands in dorsal raphe and ventral hippocampus. Pharmacol. Biochem. Behav. 54:1996;123-128.
21. 1A antagonist WAY 100135. In: Proceedings of the 2nd International Symposium on Serotonin: from cell biology to pharmacology and therapeutics. Houston; 1992:30.
22. 1A receptor antagonists. utility as research tools and therapeutic agents Trends Pharmacol. Sci. 14:1993;441-448.
23. 1A receptor antagonist. Behav. Brain Res. 73:1996;337-353.
24. 1A receptor antagonist, WAY 100635. Eur. J. Pharmacol. 281:1995;81-88.
25. Griebel G. 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders. more than 30 years of research Pharmacol. Ther. 65:1995;319-395.
26. Griebel G., Blanchard D. C., Blanchard R. J. Predator-elicited flight responses in Swiss-Webster mice. an experimental model of panic attacks Prog. Neuro. Psychopharmacol. Biol. Psychiatr. 20:1996;185-205.
27. 2A receptor antagonist S 21537. Pharmacol. Biochem. Behav. 54:1996;509-516.
28. 1A receptor antagonist has anxiogenic effects in rats and does not block stress-induced rises in stress hormones. Soc. Neurosci. Abstr. 21:1995;1366.
29. 1A antagonist is determined by arousal state. J. Psychopharmacol. 8:1994;A13.
30. Handley S. L., Mithani S. Effects of alpha-adrenoceptor agonists and antagonists in a maze-exploration model of "fear"-motivated behaviour. Naunyn-Schmiedeberg Arch. Pharmacol. 327:1984;1-5.
31. 1A agonists in rats. a new model for evaluating anxiolytic-like activity J. Psychopharmacol. 8:1994;227-237.
32. 1A partial agonists, full agonists, and antagonists in the murine elevated plus maze. Soc. Neurosci. Abstr. 21:1995;1367.
33. 1-adrenoceptors in the inhibition of 5-HT release - I. BMY7378 and prazosin. Neuropharmacology. 34:1995;615-620.
34. Hodges H., Green S., Glenn B. Evidence that the amygdala is involved in benzodiazepine and serotonergic effects on punished responding but not discrimination. Psychopharmacology. 92:1987;491-504.
35. 2A/2C antagonist anxiolytics. I. Antipunishment effects in the pigeon. J. Pharmacol. Exp. Ther. 276:1996;388-397.
36. 2 antagonists idazoxan and rauwolscine but not yohimbine or piperoxan are anxiolytic in the Vogel lick-shock conflict paradigm following intravenous administration. Life Sci. 54:1994;PL179-PL184.
37. 1A receptor ligands (+)-WAY 100135 and SDZ 216-525. Eur. J. Pharmacol. 249:1993;25-35.
38. 1A receptors in vivo. Eur. J. Pharmacol. 240:1993;307-310.
39. Lister R. G. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology. 92:1987;180-185.
40. 1A agonists. Behav. Pharmacol. 5:1994;42-51.
41. 1A autoreceptors. actions in models of antidepressive, anxiolytic and promnesic activity Soc. Neurosci. Abstr. 20:1994;1544.
42. 1A receptor antagonist (S)-UH-301 in rodents and monkeys. Brain Res. Bull. 29:1992;901-904.
43. 1A receptors on the exploratory activity of rats in the elevated plus-maze. Psychopharmacology. 107:1992;135-139.
44. 11C]WAY-100635. Eur. J. Pharmacol. 301:1996;R5-R7.
45. 1A receptors is responsible for the anticonflict effect of ipsapirone in rats. J. Pharm. Pharmacol. 44:1992;780-782.
46. 1A) receptors in the anticonflict activity of β-adrenoceptor antagonists. Neuropharmacology. 34:1995;1211-1217.
47. 1A) receptors in the anticonflict activity of α-adrenoceptor antagonists. Pharmacol. Biochem. Behav. 47:1994;873-878.
48. 1A receptors are critically involved in the anxiolytic effects of 8-OH-DPAT. Psychopharmacology. 125:1996;89-91.
49. Rodgers R. J., Cole J. C. The elevated plus-maze. pharmacology, methodology and ethology Cooper S. J., Hendrie C. A. Ethology and psychopharmacology. 1994;9-44 John Wiley & Sons, Chichester.
50. 1A receptor antagonist, in the murine elevated plus-maze test. Eur. J. Pharmacol. 261:1994;321-325.
51. Rodgers R. J., Cole J. C., Cobain M. R., Daly P., Doran P. J., Eells J. R., Wallis P. Anxiogenic-like effects of fluprazine and eltoprazine in the mouse elevated plus-maze. profile comparisons with 8-OH-DPAT, CGS 12066B, TFMPP and mCPP Behav. Pharmacol. 3:1992;621-634.
52. Rodgers R. J., Johnson N. J. T. Factor analysis of spatiotemporal and ethological measures in the elevated plus-maze test of anxiety. Pharmacol. Biochem. Behav. 52:1995;297-303.
53. 1A receptor antagonists. Behav. Brain Res. 73:1996;153-156.
54. Routledge C., Gurling J., Ashworth-Preece M., Dourish C. T. Differential effects of WAY-100135 on the decrease in 5-hydroxytryptamine release induced by buspirone and NAN-190. Eur. J. Pharmacol. 276:1995;281-284.
55. Sanchez C. Effects of serotonergic drugs on footshock-induced ultrasonic vocalization in adult male rats. Behav. Pharmacol. 4:1993;269-277.
56. Sanchez C. Serotonergic mechanisms involved in the exploratory behaviour of mice in a fully automated two-compartment black and white test box. Pharmacol. Toxicol. 77:1995;71-78.
57. 1A receptor antagonist. Eur. J. Pharmacol. 244:1993;251-257.
58. 1A receptor antagonist, SDZ 216-525, decreases 5-HT release in rat hippocampus in vivo. Br. J. Pharmacol. 109:1993;699-702.
59. 1A receptor. Behav. Pharmacol. 5(suppl. 1):1994;82.
60. Solonen M., Onaivi E. S., Maze M. Dexmedetomidine synergism with midazolam in the elevated plus-maze test in rats. Psychopharmacology. 108:1992;229-234.
61. 1A receptor antagonist in the conditioned emotional response test in rats. Behav. Pharmacol. 5(suppl. 1):1994;32.
62. Thielen R. J., Fangon N. B., Frazer A. 4-(2′-Methoxy-phenyl)-1-[2′-(N-2′-pyridinyl)-p-iodobenzamido]- ethyl-piperazine and 4-(2′-methoxy-phenyl)-1-[2′-(N-2′-pyridinyl)-p- fluorobenzamido]-ethyl-piperazine, two new antagonists at pre- and postsynaptic serotonin-1A receptors. J. Pharmacol. Exp. Ther. 277:1996;661-670.
63. Van Wijngaarden I. M., Tulp T. H. M., Soudijn W. The concept of selectivity in 5-HT receptor research. Eur. J. Pharmacol. 188:1990;301-312.
64. Wright I. K., Upton N., Marsden C. A. Effect of established and putative anxiolytics on extracellular 5-HT and 5-HIAA in the ventral hippocampus of rats during behaviour on the elevated X-maze. Psychopharmacology. 109:1992;338-346.
65. Yang X.-M., Gorman A. L., Dunn A. J. The involvement of central noradrenergic system and corticotropin-releasing factor in defensive-withdrawal behavior. J. Pharmacol. Exp. Ther. 255:1990;1064-1070.
66. Zethof T. J. J., Van der Heyden J. A. M., Tolboom J. T. B. M., Olivier B. Stress-induced hyperthermia as a putative anxiety model. Eur. J. Pharmacol. 294:1995;125-135.